HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Settlement With States Not Likely To Be Precedent In OTC Space

This article was originally published in The Pink Sheet

Executive Summary

J&J's agreement with 42 states and Washington, D.C. is its latest cost from widespread GMP problems that prompted recalls and led to a 2011 FDA consent decree. But the unusual combination of factors suggest more such state actions are unlikely to follow.

You may also be interested in...

J&J/McNeil Completes Remediation Under Consent Decree

FDA officials on Aug. 21 notified the firm that its Fort Washington, Pa., manufacturing plant is compliant with the agency’s GMP regulations for drugs.

Glaxo In Charge, And The World Is GSK/Novartis Consumer Product JV’s Oyster

GSK Consumer Healthcare not only is the name of Glaxo/Novartis JV, but also the brand being added to Novartis’ OTC products. The JV will access OTC switch opportunities across the Rx portfolios of both Glaxo and Novartis in addition to external partners, says Americas/Europe head Brian McNamara.

GNC Targets ‘Consumer Trust’ In N.Y. Agreement, But Industry Wary Of Impact

As GNC explains why it accepted an agreement with N.Y. to resolve accusations about adulterated herbal supplements, industry stakeholders at Ingredient Marketplace discuss strategies on refuting those allegations and informing consumers about the quality control that is a hallmark for much of the industry.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts